1. Home
  2. WTO vs GLTO Comparison

WTO vs GLTO Comparison

Compare WTO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WTO

UTime Limited

HOLD

Current Price

$0.87

Market Cap

2.4M

Sector

Technology

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$31.36

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTO
GLTO
Founded
2008
2011
Country
China
Denmark
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
23.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
WTO
GLTO
Price
$0.87
$31.36
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
1.6M
207.8K
Earning Date
12-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,589,265.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
54.01
N/A
52 Week Low
$0.90
$2.01
52 Week High
$440.00
$33.60

Technical Indicators

Market Signals
Indicator
WTO
GLTO
Relative Strength Index (RSI) 49.95 70.94
Support Level $1.09 $25.60
Resistance Level $1.25 $32.20
Average True Range (ATR) 0.12 3.02
MACD -0.03 0.76
Stochastic Oscillator 7.38 92.21

Price Performance

Historical Comparison
WTO
GLTO

About WTO UTime Limited

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: